Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

Lisata Acquires Marea, $225M Private Placement

Analysis based on 6 articles · First reported Sep 17, 2026 · Last updated Sep 18, 2026

Sentiment
15
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The transaction transforms Lisata into a cardioendocrine-focused company with a substantially larger shareholder base and roughly $225 million in fresh capital, which reduces near-term financing risk but brings heavy dilution to legacy holders. The deal is a modest positive for sentiment around small-cap biotech M&A and specialty pharma financing, with limited broader market spillover.

biotechnology pharmaceuticals healthcare

Lisata Therapeutics acquired Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardioendocrine diseases, in a stock-for-stock transaction. All of Marea's outstanding equity interests were exchanged for 1,793,129 shares of Lisata common stock and 211,365.213 shares of Series C non-voting convertible preferred stock, representing in aggregate 213,158,342 shares of Lisata common stock on an as-converted basis. Concurrently, Lisata entered into a definitive purchase agreement for an oversubscribed private placement of Series C non-voting convertible preferred stock expected to raise approximately $225 million in gross proceeds before expenses. Following the transactions, on a fully diluted, as-converted basis, pre-acquisition Lisata equity holders will own approximately 2.39%, Marea equity holders approximately 59.54%, and private placement investors approximately 38.07% of Lisata. Lisata plans to use the net proceeds primarily to advance Marea's lead candidates MAR001/005 for severe hypertriglyceridemia, currently in Phase 2b development, and MAR002 for acromegaly, currently in Phase 2, through key clinical milestones, with topline data from both studies expected in the fourth quarter of 2027. The financing is expected to fund operations into 2028. Lisata will continue evaluating next steps for its existing oncology candidate certepetide while prioritizing Marea's cardioendocrine pipeline. The acquisition was approved by the boards of both companies and Marea's stockholders; the private placement was not subject to Lisata stockholder approval. H.C. Wainwright & Co. advised Lisata and Leerink Partners advised Marea. Lisata shares traded at $1.47 at the previous close on Nasdaq.

90 Lisata Therapeutics secured private placement
30 RA Capital Management participated in financing Lisata Therapeutics
30 Forbion Ventures participated in financing Lisata Therapeutics
30 Third Rock Ventures participated in financing Lisata Therapeutics
30 Alpha Wave Global participated in financing Lisata Therapeutics
30 Perceptive Advisors participated in financing Lisata Therapeutics
30 Sofinnova Partners participated in financing Lisata Therapeutics
30 Omega Funds participated in financing Lisata Therapeutics
30 Nantahala Capital Management participated in financing Lisata Therapeutics
30 Affinity Asset Advisors participated in financing Lisata Therapeutics
30 VenBio participated in financing Lisata Therapeutics
30 Rock Springs Capital participated in financing Lisata Therapeutics
20 H.C. Wainwright & Co. advised on acquisition Lisata Therapeutics
+ 1 more actions View on Dashboard
stock
Acquirer that issued stock and preferred shares to buy Marea and raised about $225 million, shifting its focus to cardioendocrine assets while legacy holders are diluted to roughly 2.39%.
Importance 100.0 Sentiment 10.0
priv
Target whose equity holders receive about 59.54% of the combined company, giving its cardioendocrine pipeline MAR001/005 and MAR002 a funded path to pivotal data.
Importance 95.0 Sentiment 30.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
priv
Participated in the oversubscribed private placement financing.
Importance 40.0 Sentiment 10.0
per
Lisata CEO who framed the Marea acquisition as a milestone broadening the company into cardioendocrine diseases.
Importance 30.0 Sentiment 5.0
+ 4 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.